Revolution Medicines 주식 가격. RVMD - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

40.16

매수가

39.50

매도가

49.00

거래량

1,718,865

39.36 일간 변동폭 40.59

26.56 52주 범위 62.40

market_cap

6.756B

전일 종가

40.29

개장가

40.50

최근 거래 시간

마지막 거래 시간

재정 규모

US$ 68,637,674

VWAP

39.932

평균 볼륨(3m)

1,668,579

발행 주식

168,219,391

배당수익률

주가수익률

-0.06

주당순이익(EPS)

-2.59

매출

11.58M

순이익

-436.37M

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include R... Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.revmed.com

본부

Wilmington, Delaware, USA

설립됨

Revolution Medicines Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker RVMD. The last closing price for Revolution Medicines was US$40.29. Over the last year, Revolution Medicines shares have traded in a share price range of US$ 26.56 to US$ 62.40.

Revolution Medicines currently has 168,219,391 shares in issue. The market capitalisation of Revolution Medicines is US$6.78 billion. Revolution Medicines has a price to earnings ratio (PE ratio) of -0.06.

전체 흐름

강세

순 프리미엄

26k

Calls / Puts

100.00%

매수 / 매도

100.00%

OTM / ITM

0.00%

Sweeps 비율

0.00%

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept...

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-2.7	-6.299580028	42.86	42.97	39.48	1930154	39.9601127	CS
4	-3.84	-8.72727272727	44	45.64	39.48	1251245	42.24521131	CS
12	-7.66	-16.0184023421	47.82	62.4	39.48	1668579	49.65174724	CS
26	-6.05	-13.0924042415	46.21	62.4	39.48	1331923	47.7915957	CS
52	13.16	48.7407407407	27	62.4	26.56	1392808	41.68282743	CS
156	17.26	75.3711790393	22.9	62.4	14.08	1255729	30.59906814	CS
260	10.81	36.8313458262	29.35	62.4	14.08	949137	31.16221698	CS

RVMD - Frequently Asked Questions (FAQ)

What is the current Revolution Medicines share price?

The current share price of Revolution Medicines is US$ 40.16

How many Revolution Medicines shares are in issue?

Revolution Medicines has 168,219,391 shares in issue

What is the market cap of Revolution Medicines?

The market capitalisation of Revolution Medicines is USD 6.78B

What is the 1 year trading range for Revolution Medicines share price?

Revolution Medicines has traded in the range of US$ 26.56 to US$ 62.40 during the past year

What is the PE ratio of Revolution Medicines?

The price to earnings ratio of Revolution Medicines is -0.06

What is the cash to sales ratio of Revolution Medicines?

The cash to sales ratio of Revolution Medicines is 2.18

What is the reporting currency for Revolution Medicines?

Revolution Medicines reports financial results in USD

What is the latest annual turnover for Revolution Medicines?

The latest annual turnover of Revolution Medicines is USD 11.58M

What is the latest annual profit for Revolution Medicines?

The latest annual profit of Revolution Medicines is USD -436.37M

What is the registered address of Revolution Medicines?

The registered address for Revolution Medicines is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Revolution Medicines website address?

The website address for Revolution Medicines is www.revmed.com

Which industry sector does Revolution Medicines operate in?

Revolution Medicines operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ASSTAsset Entities Inc	US$ 0.8998 (93.71%)	263.47M
DWTXDogwood Therapeutics Inc	US$ 3.18 (70.05%)	24.31M
USEGUS Energy Corp	US$ 3.74 (61.21%)	107.79M
DOGZDogness International Corporation	US$ 27.62 (52.60%)	1.95M
MYNAMynaric AG	US$ 0.6697 (50.83%)	3.72M
GOEVCanoo Inc	US$ 0.3748 (-72.24%)	41.38M
SHOTWSafety Shot Inc	US$ 0.1094 (-47.40%)	18.06k
ORKTOrangeKloud Technology Inc	US$ 0.7068 (-36.89%)	7.48M
HEPAHepion Pharmaceuticals Inc	US$ 0.3219 (-31.36%)	1.66M
WNWMeiwu Technology Company Ltd	US$ 0.2681 (-27.05%)	11.02M
GCTKGlucoTrack Inc	US$ 0.1226 (44.41%)	613.28M
CRKNCrown Electrokinetics Corporation	US$ 0.1121 (-10.32%)	392.52M
ASSTAsset Entities Inc	US$ 0.8998 (93.71%)	262.98M
RIMEAlgorhythm Holdings Inc	US$ 0.034599 (-16.83%)	230.08M
RGTIRigetti Computing Inc	US$ 13.97 (42.12%)	226.81M